**INTRODUCTION**

A-kinase anchoring proteins (AKAPs) have been identified in a number of species and tissues and are related to the composition of a wide variety of complexes implicated in different signalling cascades. AKAPs are distinguished by their ability to bind cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) as well as other signalling enzymes at focal points within the cell to ensure the integration and processing of multiple signalling pathways.\(^1\) Additional signalling proteins including adenylyl cyclases (ACs), phosphodiesterases (PDEs), protein kinases, phosphatases, GTPases and ion channels locate on the anchoring protein. AKAPs recruit these signalling molecules and form multifunctional complexes to generate protein-protein interactions.\(^2\)–\(^4\) AKAPs have been traditionally named on the basis of their apparent molecular weight, whereas in different species, there is disparity in the naming of the same anchoring protein. Hence, the Human Genome Organisation (HUGO) gives approval for the nomenclature of the AKAPs.\(^1\)

Cyclic AMP is a widespread intracellular second messenger that regulates numerous physiological and pathological processes.
The concentration and signalling of cAMP are tightly controlled and co-ordinated through the involvement of molecular machinery co-ordinating the spatial and temporal processes of localized cAMP signalling events.\textsuperscript{5,6} Stimulating G protein-coupled receptors (GPCRs), such as β adrenergic receptor, by interacting with α subunit of G protein (Gα) promotes signal transduction through the cAMP pathway via specific extracellular ligands, leading to the activation of most ACs, which convert ATP into cAMP. Through the generation of cAMP following AC activation, cAMP-dependent PKA is activated, and ligands that stimulate GPCRs coupled to Gs can inhibit AC activity. Furthermore, cAMP may be degraded by PDEs\textsuperscript{7-10} (see Figure 1A).

The PKA holoenzyme is a heterotetramer consisting of two regulatory (R) subunits that maintain two catalytic (C) subunits in an inhibited state.\textsuperscript{11} The holoenzyme can dissociate into a regulatory subunit dimer (each monomer binds two cAMP) and two free but active catalytic subunits when binding four molecules of cAMP.\textsuperscript{12} There are three genes for the C subunit gene products, including Ca, Cβ and Cγ. The R genes have been divided into four different types: RIα, RIIα, RIIβ and RIIγ.\textsuperscript{13} Ca1, Ca2 and Ca3 are contained in Ca isoforms. Ca1 exists in a wide variety of human tissues; Ca2 is mainly expressed in sperm cells; and the expression of Ca3 remains to be elucidated. The Cβ isoform has been found in human tissues, and the function of the Cγ isoform, which is expressed in testis tissue, remains unclear.\textsuperscript{14,15} The four PKA R subunit isoforms share a universal domain organization containing the N-terminal dimerization/docking (D/D) domain, a linker including the inhibitor site, and two consecutive cAMP-binding domains. Differs in cAMP responsiveness and subcellular localization show that RI isoforms are predominantly diffuse in the cytoplasm and are more sensitive to cAMP signalling, whereas the RII isoforms are more localized in cells and less responsive to cAMP signalling.\textsuperscript{16} The RI subunits have a pseudo-substrate binding site, and the RII subunits are not only substrates but also inhibitors of the C subunit. However, the phosphorylated RII dimer does not dissociate from the C subunits in the absence of cAMP. The R subunits are tightly bound to the C subunits, thereby preventing the C subunit from interacting with external protein substrates. The cAMP-binding domain allows the cells to turn the second messenger cAMP signal into a biological response. Therefore, when the structure of PKA is changed, cAMP-dependent activation is decreased.\textsuperscript{12,17-19} AKAPs are a family of functionally related proteins that interact with the regulatory subunits of the PKA holoenzyme. Through interaction between the hydrophobic pocket of PKA and the 14-18 amino acid amphipathic helix region of AKAPs, AKAPs anchor the R subunit dimer D/D domain, and AKAPs are responsible for anchoring the two R subunits specifically. Although some AKAPs show specificity for RI and RII subunits, most AKAPs tend to show more specificity for the RII subunit than that for the RI subunit.\textsuperscript{3,20} The RIlα D/D domain can accommodate various side chains at numerous positions of the AKAP peptide; the flexible N terminus of the D/D domain is the crucial one. At many cellular microdomains, cAMP signalling is amplified by facilitating PKA interactions with many AKAPs, which results from this kind of plasticity of the D/D domain.\textsuperscript{21} Moreover, spatially restricted activation of PKA is guaranteed by the binding of this kinase with AKAPs\textsuperscript{22-24} (see Figure 1B). In contrast, a recent study has shown that even local cAMP production stimulates kinase activity, and AKAP79:2RII:2C assemblies remain intact, which means AKAP-PKA holoenzyme assemblies remain intact (see Figure 1C). cAMP production in response to physiological effectors of GPCR signalling appears not to promote catalytic subunit release from anchored PKA holoenzymes.\textsuperscript{25} But this result has been challenged recently by Gray’s group,\textsuperscript{26} which proved that catalytic subunits are released from regulatory subunits by cAMP, and during cAMP activation, tether to R subunits does not restrict C subunit activity. These views remain controversial and have yet to be explored.

Over the decades, more than 70 different AKAPs have been discovered in various cells, and accumulating evidence has indicated

**FIGURE 1** A, Stimulating GPCRs promotes signal transduction through the cAMP pathway via specific extracellular ligands leading to the activation of AC, which converts ATP into cAMP. AKAP anchors in PKA. B, cAMP binding to the R subunits of PKA increases, and the active catalytic subunits are released to phosphorylate their targets. C, This compact state may provide for the phosphorylation of associated target proteins.
that several AKAPs play key roles in modulating multiple signalling pathways in the vasculature and in the heart. By co-ordinating signalling pathways, AKAPs modulate the physiological and pathological function of cardiomyocytes and endothelial and smooth muscle cells, thereby influencing vascular and cardiac function (Table 1). AKAPs can function in the heart to influence contractility, action potential, arrhythmias, hypoxia adaptation, heart failure and hypertrophy.2,27-32 In this review, we will provide an overview of recent results describing the functional regulation of AKAPs in cardiac pathophysiology.

2 | CARDIAC HYPERTROPHY

2.1 | D-AKAP1

D-AKAP1, which means a dual-specificity A-kinase anchoring protein, binds to both the RI and RII subunits of PKA.33 Several D-AKAP1 isoforms or homologues were identified in various species. These isoforms include mouse AKAP121, rat AKAP121 and human AKAP149.34 It has been shown that down-regulation of D-AKAP1 is related to oxidative stress, mitochondrial dysfunction, cardiomyocyte hypertrophy and apoptosis.35-37 Previous studies have shown that knockdown of D-AKAP1 induces, rather than inhibits, hypertrophy. In contrast, overexpression of D-AKAP1 has the opposite effect on cell size. On one hand, cell size is reduced by increased D-AKAP1 expression. The effect of the hypertrophic adrenergic agonist isoproterenol is inhibited. The result of D-AKAP1 knockdown on hypertrophy is mediated by the activation of the calcineurin (CaN)/nuclear factor of activated T cell (NFATc) pathway, as shown by alterations in intracellular NFATc3 localization. Small hairpin RNA (shRNA) experiments have been performed to show that D-AKAP1 knockdown induces NFATc3 dephosphorylation and translocation to the nucleus, resulting in hypertrophy.35

In addition, other studies demonstrated that D-AKAP1 is an important regulator of mitochondrial function and cell survival, and thus, D-AKAP1 down-regulation may represent an important event in the development of cardiac dysfunction. Displacement of D-AKAP1 from mitochondria is closely related to increased reactive oxygen species (ROS) generation, and ROS production induces D-AKAP1 degradation. Accumulation of ROS also promotes cardiomyocyte apoptosis. This is an important observation because it suggests that improper cAMP signalling can spill over into mitochondrial regulatory pathways, connecting cardiomyocyte survival and oxidative stress.26

2.2 | mAKAP

The scaffolding protein muscle-selective AKAP (mAKAP), also known as AKAP6,38 is a PKA-anchoring partner that is expressed in the brain, heart and skeletal muscle. α and β are two alternatively spliced forms of mAKAP, which is required in cardiac myocytes for the induction of cardiac hypertrophy by transverse aortic
constriction and isoproterenol infusion. However, mAKAP-β, mainly expressed in heart and skeletal muscle, plays a crucial role in myoblast differentiation, myotube formation and muscle regeneration. The classical view is that mAKAP complex anchoring extracellular-regulated kinase 5 (ERK5) can induce cardiac hypertrophy. During the past few years, some literature has revealed several novel signalling pathways by which mAKAP regulates cardiac hypertrophy.

First, phospholipase Cε (PLCe) scaffolded to mAKAP is a multifunctional enzyme implicated in cardiovascular, pancreatic and inflammatory functions. Evidence shows that PLCε generates second messengers at the nuclear envelope that are required for hypertrophy, and phosphatidylinositol 4-phosphate (PI4P) is a perinuclear substrate in the Golgi apparatus for mAKAP-scaffolded PLCε. PI4P, together with PLCε, is a substrate for mAKAP. Activation of mAKAP-scaffolded PLCε is directly involved in perinuclear PI4P depletion, which means that, as a perinuclear enzyme, PLCε can hydrolyse PI4P to produce diacylglycerol (DAG). Notably, cardiac hypertrophy development is significantly reduced after the cardiac-specific deletion of PLCε. This strongly suggests that mAKAP-PLCε signalling in cardiac myocytes is important for hypertrophy development. Furthermore, the neonatal myocyte analysis of PLCε function is largely relevant to the function of the whole heart.

In addition, the scaffolding protein mAKAP organizes a calci-neurin/myocyte enhancer factor 2 (MEF2) signalling complex in myocytes to regulate gene transcription. In the stressed heart, MEF2 is significant for the transactivation of hypertrophic gene transcription. A laboratory used primary neonatal rat cardiac myocytes transfected with expression plasmids for either control mCherry or mCherry-CaNBD and then stimulated the cells for two days with norepinephrine, which is a type of adrenergic agonist that can increase the cross-sectional area of cells. By measuring the cellular cross-sectional area on images, it was found that there was no distinct difference in size between treated and untreated myocytes expressing mCherry-CaNBD. Meanwhile, the expression of atrial natriuretic factor (ANF), a marker for hypertrophy encoded by the MEF2-transactivated Nppa gene, was down-regulated in mCherry-CaNBD-expressing myocytes after adrenergic stimulation. Taken together, these data suggest that calcineurin binding to mAKAP is required for the induction of cardiac hypertrophy and that this event is mediated by MEF2.

Additionally, mAKAP-β contributes to the orchestration of Ca2+ dependent signalling transduction. During states of elevated sympathetic stimulation, PKA-catalysed ryanodine receptor Ca2+ release channel (RyR2) phosphorylation could increase local Ca2+ release with the participation of mAKAP-β. Ca2+ is released to induce sarcotomic contraction, and mAKAP-β complexes may connect contractility to the induction of hypertrophy. Lee et al further studied skeletal myoblast differentiation and muscle regeneration based on mAKAP. mAKAP knockdown was shown to markedly impede the formation of myotubes and decrease myoblast differentiation and skeletal muscle regeneration.

2.3 | AKAP-Lbc

AKAP-Lbc (also known as AKAP13 and Ht31) is a Rho-specific guanine nucleotide exchange factor inside cells, and it functions as a scaffolding protein to co-ordinate the Rho signalling pathway. AKAP-Lbc not only anchors PKA but can also activate Rho. Diviani’s group has undertaken a number of fundamental studies on AKAP-Lbc, and they identified AKAP-Lbc as the first Rho-guanine nucleotide exchange factor (GEF) involved in signalling pathways leading to cardiomyocyte hypertrophy by activating RhoA and transducing hypertrophic signals downstream of α1-adrenergic receptors (ARs). It has been demonstrated that AKAP-Lbc is up-regulated in human hypertrophic cardiomyopathy. However, AKAP-Lbc assembles a macromolecular signalling complex to co-ordinate the activity of transduction enzymes, which has a direct impact on compensatory hypertrophy and maintenance of cardiac function during the early-phase of cardiac remodelling.

AKAP-Lbc-ΔPKD1 is a truncated form of AKAP-Lbc that is unable to bind PKD1. Because of the deletion of the PKD1 binding domain on AKAP-Lbc, AKAP-Lbc-ΔPKD1 mice exhibit reduced myocyte hypertrophy with increased cardiac extracellular collagen synthesis and apoptosis in response to transaortic constriction (TAC)–induced pressure overload or angiotensin (AT-II) and phenylephrine (PE) infusion. Furthermore, AKAP-Lbc-ΔPKD1 mice display an altered cardiac transcriptional response to TAC-induced pressure overload, which means AKAP-Lbc-PKD1 signalling is critical for transcriptional regulation during the development of compensatory hypertrophy. However, the AKAP-Lbc/PKD1 complex has been shown to prevent mitochondrial dysfunction and cardiomyocyte death induced by doxorubicin. As a molecular platform, AKAP-Lbc co-ordinates protective signals preventing DOX-induced cardiomyocyte toxicity. Stimulation of α1-adrenergic receptors (ARs) contributes to the activation of AKAP-Lbc-anchored PKD1, and in DOX-treated cardiomyocytes, two anti-apoptotic pathways are activated to enhance the expression of Bcl2 and inhibit the mitochondrial translocation of the pro-apoptotic protein Bax. AKAP-Lbc/PKD1 complex functions to prevent mitochondrial dysfunction and cardiomyocyte death induced by DOX.

The tyrosine phosphatase Shp2 is a component of the A-kinase anchoring protein (AKAP)-Lbc complex, and the interaction of AKAP-Lbc and Shp2 inside cells is complicated. Shp2 is a PKA substrate; Shp2 is phosphorylated by PKA in cardiac myocytes in response to isoproterenol stimulation. At the same time, AKAP-Lbc plays an important role in the regulation of Shp2 activity by facilitating the phosphorylation of Shp2 by PKA. Two key amino acids in Shp2, Thr-73 and Ser-189 are phosphorylated by PKA. In summary, chronic activation of PKA in the hypertrophic heart promotes the inhibition of Shp2 activity associated with AKAP-Lbc (see Figure 2).

IκB is an inhibitor of the transcription factor NF-κB, which is a mediator of the growth responses induced by a variety of pro-hypertrophic agonists. NF-κB is recognized as a key transcription factor mediating cardiac hypertrophy. The inhibitor of IκB kinase (IKK) complex (IKKα, IKKβ and IKKγ) contributes to the phosphorylation
AKAP15 (also known as AKAP7 and AKAP18) interacts with PKA, protein kinase C (PKC), Ca²⁺/calmodulin-dependent phosphatase (CaN), calmodulin (CaM) and other signalling molecules to regulate vascular tone and blood pressure. During hyperglycaemia and diabetes, AKAP79/150 is reported to contribute to enhancing vascular tone through facilitating large-conductance Ca²⁺-activated K⁺ (BK) channel remodelling. AKAP150 anchors CaN and mediates nuclear factor of activated T cell (NFATc3) activation and the transcriptional suppression of regulatory BK-β1 subunit during diabetes induced by glucose, and the BK-β1 subunit is a crucial regulatory factor of vascular tone. In conclusion, anchoring of calcineurin by AKAP150 is required for BK channel impairment during hyperglycaemia and diabetes, which promotes enhanced vascular tone. In addition, hypercontractility of arterial myocytes and enhanced vascular tone during diabetes are attributed to the effects of increased glucose on L-type CaV1.2 channels. α₁C is a subpopulation of the CaV1.2 channel pore-forming subunit, and Ser is a highly conserved PKA consensus phosphorylation site located within the intracellular C terminus of α₁C. As a key

and reducing the channel's sensitivity, DCT is required for normal responses to β-AR signalling and AKAP15 localization. Deletion of the DCT induces cardiac hypertrophy, possibly as a result of impairment of regulation of the peripheral vasculature, such as increased peripheral vascular resistance. CaV1.2 channels without DCT cannot be regulated by the β-AR/PKA signalling pathway and cannot support normal expression and localization of AKAP15. This result underscores the importance of AKAP15 in normal excitation-contraction coupling and suggests that AKAP15 plays a role as an inhibitor of cardiac hypertrophy.

2.5 | AKAP5

Although the expression of AKAP5 (murine AKAP150, human AKAP79) in the heart is low, it is widely expressed in the periphery and plays a major role in forming discrete signalling networks. AKAP5 is able to bind and inactivate Ca²⁺/calmodulin-dependent phosphatase (CaN). On this condition, CaN-mediated cardiac hypertrophy can be inhibited. However, endogenous CaN activity does not directly regulate cardiac Ca²⁺ channel activity in mouse myocytes. AKAP5 mice with significantly diminished endogenous CaN activity can retain normal myocyte size. Cardiac β-ARs are key regulators of cardiac size. AKAP5 is a key regulator of myocardial signalling by β-ARs. Deletion of AKAP5 was associated with significant cardiac hypertrophy. Because deletion of AKAP5 prevented the recycling of internal β₁-AR, the influence did not include the internalization of β₁-AR in mouse cardiac myocytes.
molecular signalling event underlying the potentiation of CaV1.2 channel activity and vasoconstriction upon acute increases in extracellular D-glucose and diabetes, the AKAP-dependent, PKA-mediated phosphorylation of α1C at Ser1928 plays a vital role in this progression.73

The expression of transient receptor potential vanilloid 4 (TRPV4) channels is comprehensive, and they belong to a kind of Ca2+-permeable, non-selective cation channel.74 Contractile function is closely tied to TRPV4 channels in that cardiomyocyte TRPV4 is a novel mediator of enhanced contractile function early in ischaemia-reperfusion.75 Endothelial impairment can influence the regulation of vascular tone, and endothelial cells (ECs) are assumed to be an important regulator of vasodilatory function. Stimulating some receptors on ECs excites TRPV4 channels, which are localized at myoendothelial junctions (MEPs). The PKC-anchoring protein AKAP79/150 mainly localizes to MEPs, which contributes to the opening of TRPV4 and enhances local Ca2+ influx. In contrast, in hypertension, this molecular assembly is disrupted.76 However, in the sarcolemma of arterial myocytes, the PKCα-associated, AKAP150-dependent modulation of TRPV4 channels relies on the distance between these two proteins.77

3.2 | Gravin

Beta-adrenergic receptors (β-ARs), and especially β2-AR, are identified as significant regulators of cardiac contractility by activating PKA.78 Gravin, also known as AKAP12 and AKAP250, has the ability to bind β2-AR.79 Therefore, gravin plays an indispensable role in the β-AR-mediated regulation of cardiac contractility.80

In one experiment, isoproterenol (ISO) was applied in wild-type (WT) and gravin mutant (gravin-t/t) mice to detect cardiac contractility, and it was found that, at diastole, there was no obvious difference between WT and gravin-t/t mice. However, at systole, left ventricular internal dimensions (LVID) were decreased in the gravin-t/t mice compared with WT mice. Moreover, cardiomyocytes isolated from gravin-t/t mice had enhanced cardiomyocyte contractility in the presence of a proportionally lower diastolic baseline and maximum height of intracellular Ca2+ transients. These results indicated that gravin is a key factor in the desensitization/resensitization cycle of β2-AR. The signalling mechanism resulting from disruption of gravin’s scaffold is such that when the gravin gene is mutant in mice, the baseline cardiac function is increased, and contractility is enhanced in response to acute β-AR stimulation. At the same time, the phosphorylation of β2-AR is decreased, which in turn attenuates receptor desensitization.80

Li et al used right ventricles of gravin mutant (gravin-t/t) mice to test the effect of acute β-AR stimulation on cardiac contractility in vivo on the absence of gravin binding to β2-AR, PKA and other signalling molecules. It was shown that gravin-t/t muscles exhibited increased myofilament Ca2+ responsiveness while maintaining their ability to release Ca2+ from the sarcoplasmic reticulum (SR). The phenomenon revealed that, besides serving as a scaffolding protein, gravin functions as a regulator of myofilament Ca2+ sensitivity. It is obvious that gravin is an important regulator of cardiac contraction via increasing myofilament sensitivity to Ca2+.81

4 | CARDIAC ARRHYTHMIAS

4.1 | Yotiao

Yotiao is a splice variant of the AKAP9 gene and is present on the plasma membrane. Yotiao displays specificity among AC isoforms and interacts with AC 1, 2, 3 and 9. In addition, Yotiao can co-ordinate the assembly of the Ik₈₅ signalling complex.82,83

Long QT syndrome (LQTS) is a heritable arrhythmia syndrome.84 Previously, it was found that, in the heart, Yotiao (AKAP9) assembles with KCNQ1, which is short for Ik₈₅ potassium channel subunit, to regulate cardiac action potential duration (APD). Type 1 long QT syndrome (LQT1) results from the disruption of this complex.85 Further experiments were performed to explore the Yotiao missense mutational site, and S1570-Yotiao was shown to modify Yotiao/KCNQ1 interactions and PKA phosphorylation; furthermore, it also reduced the functional response of Ik₈₅ channels to cAMP. Therefore, it is obvious that, as an inherited mutation of an AKAP9-encoded protein, S1570-Yotiao is relevant to LQTS, and this finding may provide evidence for future clinical treatment.86

4.2 | AKAP150

The interaction between AKAP150 and long QT syndrome 8 (LQT8) is also known as Timothy syndrome and is characterized by a single amino acid substitution (G406R) in the L-type Ca2+ (CaV1.2) channel.87 Disruption of AKAP150 improves pathological CaV1.2-LQT8 channel gating and arrhythmias and prevents hypertrophy of LQT8 hearts by decreasing Ca2+ influx via CaV1.2-LQT8 channels.88

AKAP150 is essential for sympathetic stimulation of the Ca2+ transient. AKAP150-null mice showed unstable R-R intervals and decreased LF, indicating that the tonus of the sympathetic nerves had been modified. In addition, the AKAP5-null atrium showed a decreased contractile response to isoproterenol, which means AKAP5-null mice exhibit a modulated sympathetic nerve response.89,90

4.3 | D-AKAP2

AKAP10 (D-AKAP2) binds with high affinity to both the RI and RII regulatory subunits of PKA, and the structure of AKAP10 consists of two tandem regulators of G protein signalling (RGS)-like homology domains followed by a 27-residue PKA-binding (AKB) domain and a PSD-95/DlgA/ZO-1(PDZ)-binding motif at the C terminus.91 D-AKAP2 binds to the D/D domain of the R subunit, and the C-terminal PDZ motif binds to a PDZ domain of NHERF1, NHERF2, and PDZK1, which serves as a bridging protein to the transporter.92

When AKAP10 is mutated in mice, the sensitivity of cultured cardiac cells to cholinergic vagus nerve inputs increases. This result is the same in living mice. In addition, AKAP10-mutant mice displayed two types of spontaneous cardiac pauses. First, sinus
pauses with junctional escape beats were 40 times more frequent in homozygous AKAP10-mutant mice than in WT mice. Second, atrioventricular (AV) heart block was 15 times more frequent in homozygous AKAP10-mutant mice. Both types of pauses were typically preceded by changes characteristic of vagus nerve activity.\textsuperscript{93} Łońiewska et al demonstrated a possible association between the 1936A > G AKAP10 variant and QTc in the aboriginal European newborn population.\textsuperscript{94}

## 5 | CONCLUSIONS AND PERSPECTIVES

It has become increasingly obvious that cardiac AKAP complexes have shed new light on how local signals are co-ordinated and processed in vascular and cardiac functions. The role of protein kinase compartmentalization is critical in mediating the kinase signalling pathways and explains the development of different disease pathologies in the presence or absence of these AKAPs. All of the experiments above demonstrate the role of the AKAP signalling pathway in diseases such as cardiac hypertrophy, contractility dysfunction and arrhythmias by anchoring PKA, PKC, CaN and CaM. Furthermore, ion channels (L-type Ca\textsuperscript{2+} channels, BK channels) are also closely associated with AKAPs.\textsuperscript{73,87} On the molecular level, we believe that the implementation of new technologies related to the structural determination of large multiprotein complexes will provide new ways to understand the mechanism of how AKAP complexes function. This will help us to establish specific therapeutic approaches to AKAP-related diseases. For example, AKAPs assemble localized signalosomes positioning relevant downstream effectors near respective substrate proteins to propagate downstream signalling; however, degradation of cAMP can halt signalling. In cardiovascular system, one family of the known cAMP receptors, the exchange proteins directly activated by cAMP (EPACs), is associated with cardiovascular hypertrophy. EPAC sensor EPAC-based therapeutics represent promising alternatives for the management of cardiovascular diseases such as cardiac hypertrophy, contractility dysfunction and arrhythmias by anchoring PKA, PKC, CaN and CaM. Furthermore, ion channels (L-type Ca\textsuperscript{2+} channels, BK channels) are also closely associated with AKAPs.\textsuperscript{73,87} On the molecular level, we believe that the implementation of new technologies related to the structural determination of large multiprotein complexes will provide new ways to understand the mechanism of how AKAP complexes function. This will help us to establish specific therapeutic approaches to AKAP-related diseases. For example, AKAPs assemble localized signalosomes positioning relevant downstream effectors near respective substrate proteins to propagate downstream signalling; however, degradation of cAMP can halt signalling. In cardiovascular system, one family of the known cAMP receptors, the exchange proteins directly activated by cAMP (EPACs), is associated with cardiac hypertrophy. EPAC sensor EPAC-based therapeutics represent promising alternatives for the management of cardiovascular diseases.\textsuperscript{95} In addition, AKAPs-related arrhythmia-causing mutations will help promote progress towards better therapeutic strategies, and there remains a need for specific treatment towards individuals in a genotype-driven.

## CONFLICT OF INTEREST

The authors declare that they have no competing interest.

## AUTHORS CONTRIBUTIONS

Zhu YR and Jiang XX contributed to draft the manuscript; Zheng YG, Xiong J and Wei DP contributed to the discussion; and Zhang DM contributed to conceive and design the review, wrote and revised the manuscript.

## ORCID

Dai-Min Zhang \footnote{https://orcid.org/0000-0001-5251-3113}

## REFERENCES

1. Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context-dependent regulation of anchored enzymes. Mol Interv. 2010;10(2):86-97.
2. Ercu M, Klussmann E. Roles of A-kinase anchoring proteins and phosphodiesterases in the cardiovascular system. J Cardiovasc Dev Dis. 2018;5(1):14.
3. Skroblin P, Grossmann S, Schaper F, et al. Mechanisms of protein kinase A anchoring. Int Rev Cell Mol Biol. 2010;283:235-330.
4. Redden JM, Dodge-Kafka KL. AKAP phosphatase complexes in the heart. J Cardiovasc Pharmacol. 2011;58(4):354-362.
5. Bastug-Ozel Z, Wright PT, Kraft AE, et al. Heart failure leads to altered beta2-adrenoceptor/cAMP dynamics in the sarcolemmal phospholemman/Na, K ATPase microdomain. Cardiovasc Res. 2018;115:546-555.
6. Dodge-Kafka KL, Bauman A, Kapiloff MS. A-kinase anchoring proteins as the basis for Cardiac signaling. Handb Exp Pharmacol. 2008;186:3-14.
7. Sassone-Corsi P. The cyclic AMP pathway. Cold Spring Harb Perspect Biol. 2012;4(12):a011148.
8. Yan K, Gao LN, Cui YL, et al. The cyclic AMP signaling pathway: Exploring targets for successful drug discovery. Mol Med Rep. 2016;13(9):3715-3723.
9. Hayes JS, Brunton LL, Mayer SE. Selective activation of particulate Camp- dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem. 1980;255(11):5113-5119.
10. Walsh DA, Perkins JP, Krebs EG. An adenosine 3’,5’-monophosphate-dependent protein kinase from rabbit skeletal muscle. J Biol Chem. 1968;243(13):3763-3765.
11. Taylor SS, Buechler JA, Yonemoto W. Camp-dependent protein kinase: frame- work for a diverse family of regulatory enzymes. Annu Rev Biochem. 1990;59:971-1005.
12. Roskoski RJ. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1-23.
13. Scott JD, Stofoke RE, McDonald JR, et al. Type II regulatory subunit dimerization determines the subcellular localization of the Camp- dependent protein kinase. J Biol Chem. 1990;265(35):21561-21566.
14. Turnham RE, Scott JD. Protein kinase A catalytic subunit isoform PRKACA: History, function and physiology. Gene. 2016;577(2):101-108.
15. Soberg K, Jahnson T, Rognes T, et al. Evolutionary paths of the Camp-dependent protein kinase (PKA) catalytic subunits. PLoS ONE. 2013;8(4):e60935.
16. Burns-Hamuro LL, Ma Y, Kammerer S, et al. Designing isoform-specific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci USA. 2003;100(7):4072-4077.
17. Kim C, Xiong NH, Taylor SS. Crystal structure of a complex between the catalytic and regulatory (Ralpha) subunits of PKA. Science. 2005;307(5710):690-696.
18. Kim C, Cheng CY, Saldanha SA, et al. PKA-I holoenzyme structure reveals a mechanism for Camp-dependent activation. Cell. 2007;130(6):1032-1043.
19. Bruystens JG, Wu J, Fortezzo A, et al. Structure of a PKA Ralpha recurrent acrodysostosis mutant explains defective camp-dependent activation. J Mol Biol. 2016;428(24 Pt B):4890-4904.
20. Mauban JR, O’Donnell M, Warrier S, et al. AKAP-scaffolding proteins and regulation of cardiac physiology. Physiology (BETHESDA). 2009;24:78-87.
21. Kinderman FS, Kim C, von Daake S, et al. A dynamic mechanism for AKAP binding to RII isoforms of Camp-dependent protein kinase. Mol Cell. 2006;24(3):397-408.

22. Carr DW, Stofko-Hahn RE, Fraser ID, et al. Interaction of the regulatory subunit (RII) of Camp-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem. 1991;266(22):14188-14192.

23. Calejo AI, Taskén K. Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins. Front Pharmacol. 2015;6:192.

24. Autenrieth K, Bendzunas NG, Bertinetti D, et al. Defining A-kinase anchoring protein (AKAP) specificity for the protein kinase A subunit RI (PKA-RI). ChemBioChem. 2016;17(8):693-697.

25. Smith FD, Esseltine JL, Nygren PJ, et al. Local protein kinase A action proceeds through intact holoenzymes. Science. 2017;356(6344):1288-1293.

26. Walker-Gray R, Stengel F, Gold MG. Mechanisms for restraining cAMP-depend protein kinase revealed by subunit quantitation and cross-linking approaches. Proc Natl Acad Sci USA. 2017;114(39):10414-10419.

27. Zoccarato A, Surdo NC, Aronsen JM, et al. Cardiac hypertrophy is orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Clin Perspect Circ: Heart Failure. 2014;7(4):663-672.

28. Li X, Matta SM, Sullivan RD, et al. Carvedilol reverses cardiac in hypertrophic signaling. J Biol Chem. 2011;286(26):23012-23021.

29. Zang L, Malik S, Kelley GG, et al. Phospholipase Cε scaffolds to muscle-specific A kinase anchoring protein (mAKAP) and integrates multiple hypertrophic stimuli in cardiac myocytes. J Biol Chem. 2011;286(26):23012-23021.

30. Nieves-Cintron M, Hirenallur-Shanthappa D, Nygren PJ, et al. AKAP150 participates in calcineurin/NFAT activation during cardiac cell hypertrophy. Cell. 2013;153(1):216-227.

31. Kim Y, Phan D, van Rooij E, et al. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest. 2008;118(1):124-132.

32. Li J, Vargas M, Kaploff MS, et al. Regulation of MEF2 transcriptional activity by calcineurin/Makap complexes. Exp Cell Res. 2013;319(4):447-454.

33. Klussmann E, Edemir B, Pepperle B, et al. Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling. Febs Lett. 2001;507:264-268.

34. Diviani D, Soderling J, Scott JD. AKAP-Lbc anchors protein kinase A and nucleates Gu12-selective Rho-mediated stress fiber formation. J Biol Chem. 2001;276(47):44247-44257.

35. Appert-Collin A, Cotecchia S, Nenninger-Tosato M, et al. The A-kinase anchoring protein (AKAP)-Lbc-signaling complex mediates alpha1 adrenergic receptor-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 2007;104(24):10140-10145.

36. Carnegie GK, Soughayer J, Smith FD, et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell. 2008;32(2):169-179.

37. Taglieri DM, Johnson KR, Burmeister BT, et al. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy. J Mol Cell Cardiol. 2014;66:27-40.

38. Johnson KR, Nicodemus-Johnson J, Spindler MJ, et al. Genome-wide gene expression analysis shows AKAP13-mediated PKD1 signaling regulates the transcriptional response to cardiac hypertrophy. PLoS ONE. 2015(10):e132477.

39. Caso S, Maric D, Arambasic M, et al. AKAP-Lbc mediates protection against doxorubin-in-induced cardiomyocyte toxicity. Biochimica et Biophysica Acta (BBA)-Molecular Cell Res. 2017;1864(12):2336-2346.

40. Burmeister BT, Taglieri DM, Wang L, et al. Src homology 2 domain-containing phosphatase 2 (Shp2) is a component of the A-kinase anchoring protein (AKAP)-Lbc complex and is inhibited by protein kinase A (PKA) under pathological hypertrophic conditions in the heart. J Biol Chem. 2012;287(48):40535-40546.

41. Burmeister BT, Wang L, Gold MG, et al. Protein Kinase A (PKA) phosphorylation of Shp2 protein inhibits its phosphatase activity and modulates ligand specificity. J Biol Chem. 2015;290(19):12058-12067.

42. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-κB signaling in heart. J Mol Cell Cardiol. 2006;41(4):580-591.

43. Freund C, Schmidt-Ullrich R, Baurand A, et al. Requirement of nutrient factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005;111(18):2319-2325.

44. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene. 2006;25(51):6685-6705.

45. Lee KH, Jang Y, Chung JH. Heat shock protein 90 regulates I kappaB kinase complex and NF-kappaB activation in angiotensin II-induced cardiac cell hypertrophy. Exp Mol Med. 2010;42(10):703-711.
60. Del Vescovo CD, Cotecchia S, Diviani D. A-kinase-anchoring protein-Lbc anchors I B kinase to support interleukin-6-mediated cardiomyocyte hypertrophy. Mol Cell Biol. 2012;32(1):14-27.

61. Soni S, Scholten A, Vos MA, et al. Anchored protein kinase A signalling in cardiac cellular electrophysiology. J Cell Mol Med. 2014;18(11):2135-2146.

62. Jones BW, Brunet S, Gilbert ML, et al. Cardiomyocytes from AKAP7 knockout mice respond normally to adrenergic stimulation. Proc Natl Acad Sci USA. 2012;109(42):17099-17104.

63. Hulme JT, Lin TW, Westenbroek RE, et al. Beta-adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15. Proc Natl Acad Sci USA. 2003;100(22):13093-13098.

64. Lygren B, Carlson CR, Santamaria K, et al. AKAP complex regulates Ca^2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007;8(11):1061-1067.

65. Fu Y, Westenbroek RE, Yu FH, et al. Deletion of the distal C terminus of CaV1.2 channels leads to loss of β-adrenergic regulation and heart failure in vivo. J Biol Chem. 2011;286(14):12617-12626.

66. Yatani A, Honda R, Tymitz KM, et al. Enhanced Ca^2+ channel function during beta1-adrenergic regulation. J Biol Chem. 2011;286(14):12617-12626.

67. Hulme JT, Westenbroek RE, Scheuer T, et al. Phosphorylation of a-kinase-anchoring protein Yotiao binds and regulates adenylyl cyclase in brain. Proc Natl Acad Sci USA. 2008;105(37):13835-13840.

68. Jones JL, Peana D, Veteto AB, et al. TRPV4 increases cardiomyocyte calcium cycling and contractility yet contributes to damage downstream of PKA phosphorylation. Proc Natl Acad Sci USA. 2017;114(20):5334-5339.

69. Faux MC, Scott JD. Regulation of the AKAP79-protein kinase anchoring protein Yotiao on a heart potassium channel. Proc Natl Acad Sci USA. 2014;111(49):16374-16379.

70. Li X, Nooh MM, Bahouth SW. Role of AKAP79/150 protein in beta1-adrenergic receptor trafficking and signaling in mammalian cells. J Biol Chem. 2013;288(47):33797-33812.

71. Sachse G, Fahlbauer J, Sieniuk A, et al. Smooth muscle BK channel activity influences blood pressure independent of vascular tone in mice. J Physiol. 2014;592(12):2563-2574.

72. Navedo MF, Santana LF. CaV1.2 sparklets in heart and vascular smooth muscle. J Mol Cell Cardiol. 2013;58:67-76.

73. Nystoriak MA, Nieves-Cintron M, Patriarchi T, et al. Ser1928 phosphorylation by PKA stimulates the L-type Ca^2+ channel CaV1.2 and vasodilation in arterial cells. J Biol Chem. 2005;280(23):22337-22344.

74. Sarma GN, Moody IS, Ilouz R, et al. D-AKAP2: PKA RII: PDZK1 ternary complex structure: Insights from the nucleation of a polyvalent scaffold. Protein Sci. 2015;24(1):105-116.

75. Smith FD, Langeberg LK, Cellurale C, et al. Force development and intracellular Ca(2+) in intact cardiac muscles from gravin mutant mice. Eur J Pharmacol. 2017;807:117-126.

76. Ueno T, Nomura R, Watanabe N, et al. A novel protein kinase A anchoring protein with a putative RGS domain. Proc Natl Acad Sci USA. 2002;99(20):12951-12956.

77. Tajada S, Moreno CM, D’Owrey S et al. Distance constraints on activation of TRPV4 channels by AKAP150-bound PKCα in arterial myocytes. J Gen Physiol. 2017;149(6):639-659.

78. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198-205.

79. Lin F, Wang H, Malbon CC. Gravin-mediated formation of signaling complexes in beta 2-adrenergic receptor desensitization and resensitization. J Biol Chem. 2000;275(25):19025-19034.

80. Guillory AN, Yin X, Wijaya CS, et al. Enhanced cardiac function in Gravin mutant mice involves alterations in the beta-adrenergic receptor signaling cascade. PLoS ONE. 2013;8(9):e74784.

81. Li Z, Singh S, Suryavanshi SV, et al. Force development and intracellular Ca(2+) in intact cardiac muscles from gravin mutant mice. Eur J Pharmacol. 2017;807:117-126.

82. Kurokawa J, Mitoike HK, Rao J, et al. Regulatory actions of the A-kinase anchoring protein Yotiao on a heart potassium channel downstream of PKA phosphorylation. Proc Natl Acad Sci USA. 2004;101(46):16374-16378.

83. Piggott LA, Bauman AL, Scott JD, et al. The A-kinase anchoring protein Yotiao binds and regulates adenylyl cyclase in brain. Proc Natl Acad Sci USA. 2008;105(37):13835-13840.

84. Mao XL. Long QT syndrome: from channels to cardiac arrhythmias. J Clin Invest. 2005;115(8):2018-2024.

85. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1/KCNE1 potassium channel. Science. 2002;295(5554):496-499.

86. Chen L, Markwardt ML, Tester DJ, et al. Mutation of a A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA. 2007;104(52):20990-20995.

87. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119(1):19-31.

88. Cheng EP, Yuan C, Navedo MF, et al. Restoration of normal L-Type Ca^2+ channel function during timothy syndrome by ablation of an anchoring protein. Circ Res. 2011;109(3):255-261.

89. Nichols CB, Rossow CF, Navedo MF, et al. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res. 2010;107(6):747-756.

90. Han C, Tomita H, Obha T, et al. Modified sympathetic nerve regulation in AKAP5-null mice. Biochem Biophys Res Commun. 2016;469(4):897-902.

91. Huang LJ, Durick K, Weiner JA, et al. D-AKAP2, a novel protein kinase A anchoring protein with a putative RGS domain. Proc Natl Acad Sci USA. 1997;94(21):11184-11189.

92. Sarma GN, Moody IS, Ilouz R, et al. D-AKAP2: PKA RII: PDZK1 ternary complex structure: Insights from the nucleation of a polyvalent scaffold. Protein Sci. 2015;24(1):105-116.

93. Tingley WG, Pawlikowska L, Zaroff JG, et al. Gene-trapped mouse embryonic stem cell-derived cardiac myocytes and human genetics implicate AKAP10 in heart rhythm regulation. Proc Natl Acad Sci USA. 2007;104(20):8461-8466.

94. Loniewska B, Kaczmarczyk M, Clark JS, et al. Association of functional genetic variants of A-kinase anchoring protein 10 with QT interval length in full-term Polish newborns. Arch Med Sci. 2015;11(1):149-154.

95. Robichaux WG III, Cheng X. Intracellular cAMP sensor EPAC: Physiology, pathophysiology, and therapeutics development. Physiol Rev. 2018;98(2):919-1053.

96. Schulze DH, Muqhal M, Lederer WJ, et al. Sodium/calcium exchanger (NCX1) macromolecular complex. J Biol Chem. 2003;278(31):28849-28855.

97. Pare GC, Easlick JL, Mislow JM, et al. Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res. 2005;303(2):38-48.

98. Martinez EC, Passariello CL, Li J, et al. RSK3: A regulator of pathological cardiac remodeling and heart failure propensity by disrupting calcium cycling and contractility yet contributes to damage downstream of PKA phosphorylation. Proc Natl Acad Sci USA. 2007;104(20):8461-8466.

99. Nicholls CB, Rossow CF, Navedo MF, et al. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res. 2010;107(6):747-756.
101. Singh A, Redden JM, Kapiloff MS, et al. The large isoforms of A-kinase anchoring protein 18 mediate the phosphorylation of inhibitor-1 by protein kinase A and the inhibition of protein phosphatase 1 activity. Mol Pharmacol. 2011;79(3):533-540.

102. Cardone L, Carlucci A, Affaitati A, et al. Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol Cell Biol. 2004;24(11):4613-4626.

103. Chaturvedi D, Poppleton HM, Stringfield T, et al. Subcellular localization and biological actions of activated RSK1 are determined by its interactions with subunits of cyclic AMP-dependent protein kinase. Mol Cell Biol. 2006;26(12):4586-4600.

104. Meiri D, Greeve MA, Brunet A, et al. Modulation of Rho guanine exchange factor Lfc activity by protein kinase A-mediated phosphorylation. Mol Cell Biol. 2009;29(21):5963-5973.

105. Nikandrova YA, Jiao Y, Baucum AJ, et al. Ca^{2+}/calmodulin-dependent protein kinase II binds to and phosphorylates a specific SAP97 splice variant to disrupt association with AKAP79/150 and modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor (AMPAR) activity. J Biol Chem. 2010;285(2):923-934.

106. Bavencoffe A, Li Y, Wu Z, et al. Persistent electrical activity in primary nociceptors after spinal cord injury is maintained by scaffolded adenylyl cyclase and protein Kinase A and is associated with altered adenylyl cyclase regulation. J Neurosci. 2016;36(5):1660-1668.

107. Havekes R, Canton DA, Park AJ et al. Gravin orchestrates protein kinase A and ß2-adrenergic receptor signaling critical for synaptic plasticity and memory. J Neurosci. 2012;32(50):18137-18149.

108. Schott MB, Grove B. Receptor-mediated Ca^{2+} and PKC signaling triggers the loss of cortical PKA compartmentalization through the redistribution of gravin. Cell Signal. 2013;25(11):2125-2135.

109. Li Y, Chen L, Kass RS, et al. The A-kinase anchoring protein Yotiao facilitates complex formation between adenylyl cyclase type 9 and the IKs potassium channel in heart. J Biol Chem. 2012;287(35):29815-29824.

110. Berryman MA, Goldenring JR. CLIC4 is enriched at cell-cell junctions and colocalizes with AKAP350 at the centrosome and midbody of cultured mammalian cells. Cell Motil Cytoskeleton. 2003;56(3):159-172.

How to cite this article: Zhu Y-R, Jiang X-X, Zheng Y, Xiong J, Wei D, Zhang D-M. Cardiac function modulation depends on the A-kinase anchoring protein complex. J Cell Mol Med. 2019;23:7170-7179. https://doi.org/10.1111/jcmm.14659